Literature DB >> 16897045

[Hand-foot syndrome with capecitabine therapy].

A Marini1, U R Hengge.   

Abstract

A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine. We also summarize the current knowledge with regard to the hand-foot syndrome and distinguish it from palmoplantar erythrodysesthesia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 16897045     DOI： 10.1007/s00105-006-1183-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  35 in total

1.  High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.

Authors:  Y H Park; B-Y Ryoo; H J Lee; S A Kim; J-H Chung
Journal:  Ann Oncol       Date:  2003-11       Impact factor: 32.976

2.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.

Authors:  C J Fabian; R Molina; M Slavik; S Dahlberg; S Giri; R Stephens
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  Hand-foot syndrome in sickle cell disease.

Authors:  F Rosner
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.

Authors:  Dorothee Eich; Karin Scharffetter-Kochanek; Hans Theodor Eich; Iliana Tantcheva-Poor; Thomas Krieg
Journal:  Am J Clin Oncol       Date:  2002-12       Impact factor: 2.339

5.  Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin.

Authors:  U R Hengge; S Esser; H P Rudel; M Goos
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

6.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.

Authors:  S J Vukelja; W J Baker; H A Burris; J H Keeling; D Von Hoff
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

7.  Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.

Authors:  M M Asgari; J G Haggerty; J M McNiff; L M Milstone; P M Schwartz
Journal:  J Cutan Pathol       Date:  1999-07       Impact factor: 1.587

8.  Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.

Authors:  S A Elasmar; E D Saad; P M Hoff
Journal:  Jpn J Clin Oncol       Date:  2001-04       Impact factor: 3.019

9.  Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.

Authors:  J Nemunaitis; R Eager; T Twaddell; A Corey; K Sekar; K Tkaczuk; J Thompson; P M Hoff; R Pazdur
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

10.  Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.

Authors:  Y F Hui; J E Cortes
Journal:  Pharmacotherapy       Date:  2000-10       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.